{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:40:53Z","timestamp":1777934453872,"version":"3.51.4"},"reference-count":28,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cytarabine is widely used to treat leukemia and lymphoma. Currently, Cyrabol\u00ae, powder for injection, is one of the specialties marketed in Tunisia. However, no stability data when diluted with 0.9% NaCl are available. The aim of this study is to evaluate the physical and chemical stability of cytarabine (Cyrabol\u00ae) solution after dilution in 0.9% NaCl (1\u2009mg\/mL, 5\u2009mg\/mL and 10\u2009mg\/mL) in polypropylene syringes under different storage conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cytarabine solutions (1\u2009mg\/mL, 5\u2009mg\/mL and 10\u2009mg\/mL) in 0.9% NaCl were prepared in polypropylene syringes and stored for 28\u2009days under different conditions. Cytarabine preparations in glass containers were prepared as a control to detect any adsorption. Chemical stability was assessed by a stability-indicating high-performance liquid chromatography method. The stability-indicating capacity of the method was proved by forced degradation tests. Linearity, precision and limit of detection and quantification were performed according to the International Conference on Harmonisation recommendations. Physical stability was checked by visual inspection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The method was proven to be a validated stability-indicating assay. At 2\u20138\u00b0C, all tested solutions were chemically stable for 28\u2009days. However, at 25\u00b0C, the main degradation product gradually increased during the study and the chemical stability of 1\u2009mg\/mL, 5\u2009mg\/mL and 10\u2009mg\/mL solutions was 14\u2009days, 8\u2009days and 5\u2009days, respectively. Similar results were observed in the glass containers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The highest physical and chemical stability of cytarabine diluted in 0.9% NaCl in polypropylene syringes was observed at 2\u20138\u00b0C. At 25\u00b0C, better stability was found in the 1\u2009mg\/mL solution compared with those at higher concentrations (5\u2009mg\/mL and 10\u2009mg\/mL).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155220937405","type":"journal-article","created":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T02:16:08Z","timestamp":1593569768000},"page":"827-833","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Physical and chemical stability of cytarabine in polypropylene syringes"],"prefix":"10.1177","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2101-7288","authenticated-orcid":false,"given":"Wiem Ben","family":"Ayed","sequence":"first","affiliation":[{"name":"National Center for Bone Marrow Transplantation, Tunis, Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chema","family":"Drira","sequence":"additional","affiliation":[{"name":"National Center for Bone Marrow Transplantation, Tunis, Tunisia"},{"name":"Faculty of Pharmacy of Monastir, University of Monastir, Monastir, Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Ali","family":"Soussi","sequence":"additional","affiliation":[{"name":"National Center for Bone Marrow Transplantation, Tunis, Tunisia"},{"name":"Faculty of Pharmacy of Monastir, University of Monastir, Monastir, Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanen","family":"Ouesleti","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy of Monastir, University of Monastir, Monastir, Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Besma","family":"Hamdene","sequence":"additional","affiliation":[{"name":"National Center for Bone Marrow Transplantation, Tunis, Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myriam","family":"Khrouf","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy of Monastir, University of Monastir, Monastir, Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fathi","family":"Safta","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy of Monastir, University of Monastir, Monastir, Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ines","family":"Fradi","sequence":"additional","affiliation":[{"name":"National Center for Bone Marrow Transplantation, Tunis, Tunisia"},{"name":"Faculty of Pharmacy of Monastir, University of Monastir, Monastir, Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,6,30]]},"reference":[{"key":"bibr1-1078155220937405","doi-asserted-by":"crossref","unstructured":"El-Subbagh HI, Al-Badr AA. Cytarabine. In: Brittain HG (ed)\n                      Profiles of drug substances, excipients and related methodology\n                      . Cambridge, MA: Elsevier, 2009, pp.37\u2013113.","DOI":"10.1016\/S1871-5125(09)34002-9"},{"key":"bibr2-1078155220937405","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241100-00002"},{"key":"bibr3-1078155220937405","doi-asserted-by":"publisher","DOI":"10.1684\/bdc.2011.1476"},{"key":"bibr4-1078155220937405","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6112"},{"key":"bibr5-1078155220937405","unstructured":"Summary of product characteristics, CYTARABINE EG 50 mg\/ml, injectable solution, summary of product characteristics, http:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/rcp\/R0201538.htm (2013, accessed 10 June 2020)."},{"key":"bibr6-1078155220937405","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199806043382304"},{"key":"bibr7-1078155220937405","unstructured":"Summary of product characteristics, CYTARABINE ACCORD 100 mg\/ml solution for injection or infusion, http:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/frames.php?specid=63318475&typedoc=R&ref=R0342618.htm (2019, accessed 10 June 2020)."},{"key":"bibr8-1078155220937405","unstructured":"Summary of product characteristics, CYTARABINE EBEWE 50 mg\/ml solution for injection, http:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/frames.php?specid=69140809&typedoc=R&ref=R0324343.htm (2018, accessed 10 June 2020)."},{"key":"bibr9-1078155220937405","unstructured":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit, CYTARABINE EG 20 mg\/ml solution for injection, http:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/frames.php?specid=69493862&typedoc=R&ref=R0320577.htm (2018, accessed 10 June 2020)."},{"key":"bibr10-1078155220937405","unstructured":"Summary of product characteristics, CYTARABINE SANDOZ 100 mg\/ml solution for injection, http:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/frames.php?specid=64762878&typedoc=R&ref=R0324647.htm (2018, accessed 10 June 2020)."},{"key":"bibr11-1078155220937405","unstructured":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit, CYTARABINE KABI 100 mg\/ml solution for injection or infusion, http:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/frames.php?specid=69333402&typedoc=R&ref=R0219949.htm (2013, accessed 10 June 2020)."},{"key":"bibr12-1078155220937405","unstructured":"Summary of product characteristics, CYTOSAR 100 mg, 500 mg, 1 g, 2 g, solution for infusion, http:\/\/www.pfizerpro.com.pk\/sites\/g\/files\/g10059366\/f\/201712\/LPD%20cytarabine%20-%20Cytosar.pdf (2017, accessed 6 September 2019)."},{"key":"bibr13-1078155220937405","unstructured":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit, ARACYTIN 2 g IV, lyophilizate for parenteral use, http:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/rcp\/R0225442.htm (2013, accessed 10 June 2020)."},{"key":"bibr14-1078155220937405","doi-asserted-by":"publisher","DOI":"10.1016\/0031-6865(95)00007-V"},{"key":"bibr15-1078155220937405","first-page":"965","volume":"31","author":"Zhang Y","year":"1996","journal-title":"Hosp Pharm"},{"key":"bibr16-1078155220937405","first-page":"53","volume":"12","author":"Weir P","year":"1990","journal-title":"Br J Pharm Pract"},{"key":"bibr17-1078155220937405","doi-asserted-by":"publisher","DOI":"10.1177\/106002808201601011"},{"key":"bibr18-1078155220937405","unstructured":"USP. Monographie cytarabin for injection\n                      . USP Monographs\n                      , 2017, p.534."},{"key":"bibr19-1078155220937405","first-page":"89","volume":"17","author":"Ellie C","year":"2007","journal-title":"STP Pharma Prat"},{"key":"bibr20-1078155220937405","doi-asserted-by":"crossref","unstructured":"Bardin C, Astier A, Vulto A, et\u00a0al. Guidelines for the practical stability studies of anticancer drugs: a European consensus conference. In:\n                      Annales pharmaceutiques francaises\n                      . Cambridge, MA: Elsevier, 2011, pp.221\u2013231.","DOI":"10.1016\/j.pharma.2011.07.002"},{"key":"bibr21-1078155220937405","unstructured":"USP. Chropatography\/physical tests, general chapters.\n                      USP Monographs\n                      , 2017, p.518."},{"key":"bibr22-1078155220937405","unstructured":"International Conference on Harmonisation.\n                      Validation of analytical procedures: text and methodology Q2(R1).\n                      Gen\u00e8ve: ICH, 2015."},{"key":"bibr23-1078155220937405","doi-asserted-by":"crossref","unstructured":"Sewell G, Bardin C, Astier A, et\u00a0al. Guidelines for the practical stability studies of anticancer drugs: a European consensus conference.\n                      Annales pharmaceutiques francaises\n                      2011; 69: 221\u2013231.","DOI":"10.1016\/j.pharma.2011.07.002"},{"key":"bibr24-1078155220937405","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600610803"},{"key":"bibr25-1078155220937405","first-page":"160","volume":"7","author":"Bhatnagar A","year":"2012","journal-title":"Eurasian J Anal Chem"},{"key":"bibr26-1078155220937405","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/49.3.619"},{"key":"bibr27-1078155220937405","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp110208"},{"key":"bibr28-1078155220937405","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5173(99)00175-1"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220937405","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155220937405","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220937405","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:23:17Z","timestamp":1777688597000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155220937405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,30]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1177\/1078155220937405"],"URL":"https:\/\/doi.org\/10.1177\/1078155220937405","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,30]]}}}